ET-D5
Image 13 of 36
Less

ET-D5: Oral chemotherapy

ET-D5_013.jpg

Add to Lightbox Download

Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.

Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.

Copyright
Bruno Vigneron
Image Size
5000x3337 / 12.1MB
Keywords
Dr Aurélie Juhem and Dr Andrei Popov are analyzing fluorescence microscopy images.<br /> <br /> Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br /> Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.